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Abstract
Background In view of the serious health risks and high
costs to the health-care system of misuse and abuse of over-
the-counter (OTC) analgesics, this article describes a
rationale and prototype for new safety or compliance
packaging for OTC drug products that are sold in pill form
(e.g., tablets, caplets and gelcaps) inside blister packs. The
proposed packaging is not simply promoting the use of
blister packs for pills; that utility is already well known. It
is an integrated system in which blister packs of pills can,
themselves, be packaged, labeled and sold, offering a dose-
directed unit-of-use design with enhanced warnings and
directions to help prevent consumers from taking more than
the instructed dose of pill-form medicines.
Method Literature and information searches were conducted
in publicly available databases and websites to (1) assess
safety problems (serious adverse events and fatalities)
associated with OTC analgesics and (2) determine public
perceptions and knowledge about their use.
Results Each year in the US, there are an estimated 100,000
hospitalizations and 16,500 deaths due to NSAID over-
dosing, and 26,000 hospitalizations and 1,600 acute liver
failure cases due to acetaminophen poisoning. Many adults
take more than the recommended dose and in some cases
use multiple products containing acetaminophen and
ibuprofen. Risk factors, such as alcohol use or pre-existing
liver disease, exacerbate problems associated with acet-
aminophen misuse and abuse. In pediatric cases, dosing
errors are often related to confusion over different product
formulations, dosing strengths, and the use of inappropriate
dosing devices. Consumers are often unaware of the active
ingredients in, and correct doses of, drugs they are taking;
they underestimate the risks associated with misuse of OTC
medicines, and they frequently discard the packaging on
which the drug’s directions, warnings and dosing instruc-
tions are located.
Conclusion Optimal compliance packaging should (1) keep
the instructions, warnings and dosing directions attached to
the blister card of pills at all times, thus avoiding the problem
of cartons and package inserts being thrown away once the
package is opened; (2) increase the surface area of the
packaging, without adding bulk, to provide space for the use
of larger font sizes and enhanced directions and warnings that
are more conspicuous, explicit and memorable; (3) organize
the pills into logical, unit-of-use (per-dose maximum and per-
day maximum) sets or rows; (4) limit the number of pills in a
unit-of-use package to coincide with the instructed maximum
dose and maximum days of use for a specific product.
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Introduction
Acetaminophen (also known as paracetamol or APAP) and
non-steroidal anti-inflammatory drugs (NSAIDs), such as
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The term “compliance packaging” is used for this prototype because it
is packaging designed to increase consumer compliance and to
distinguish it from the more commonly known child-proof safety
packaging or tamper-evident packaging.
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ibuprofen, are well-known analgesics available over the
counter (OTC) for relief of minor aches and pains and for
temporary reduction of fever. Estimates of acetaminophen
and NSAID use vary, but they indicate ubiquitous and
frequent use (Amar and Schiff 2007; National Consumers
League 2003). According to the Consumer Healthcare
Products Association (CHPA 2002), 160 million American
adults rely on OTC analgesics to relieve pain or reduce
fever in any given week. In addition to their role as single-
ingredient pain relievers, acetaminophen or ibuprofen is
present in numerous combination OTC products that are
used for cough-cold and allergy-sinus relief.
However, particularly important safety concerns (organ-
specific risks) apply to these analgesics if they are taken in
excess of the recommended dose, or for too many days, or
in contradiction to the labeled warnings. Yet research
reveals that 44% of US adults who take OTC pain relievers
admit to ignoring label warnings and exceeding the
recommended dose (National Consumers League 2003),
and only about 2% of adults actually know the correct daily
dose of popular analgesics that they take on a regular basis
(Stumpf et al. 2007).
The compliance packaging described in this article
utilizes evidence-based methods to package and label
OTC drugs in order to enhance consumer assimilation of
dosing directions and warning information, and maximize
compliance with the label instructions. The prototype
increases the surface area of the packaging to accommodate
larger, more conspicuous and explicit warnings and dosing
directions without adding bulk. It also increases the
probability that the drug’s instructions will remain attached
to the drug product, thus enhancing the communication of
crucial information that might otherwise be discarded or
ignored by consumers. The objective is to provide more
functional unit-of-use packaging that facilitates the noticing,
reading and keeping of drug instructions. Any additional
packaging cost will, hopefully, be outweighed by the benefit
of saving lives and health-care dollars.
Use, misuse and abuse of OTC analgesics
Acetaminophen hepatoxicity
A population-based study by Bower et al. (2007) suggests
that approximately 1,600 acute liver failure (ALF) cases
occur in the US each year, with acetaminophen-related ALF
being the most common etiology. Larson (2007) reports
that APAP was responsible for 51% of ALF cases in the US
in 2003. In one prospective study of 308 ALF cases, over
two-thirds of the consumers took more than 4 g of
acetaminophen per day, and in 32% of those cases
consumers took more than 10 g per day (Ostapowicz et
al. 2002). Over 4 g per day of acetaminophen for long
periods is considered abuse (Abbott and Fraser 1998).
According to Nourjah et al. (2006), APAP-associated
overdoses (unintentional and intentional) accounted for
about 56,000 emergency department visits each year
between 1993 and 1999, about 26,000 hospitalizations each
year between 1990 and 1999, and an average of 458 deaths
each year in 1996, 1997 and 1998. In 1995, Bond and
Novak estimated the annual health-care costs associated
with all US intentional adult and adolescent acetaminophen
self-poisoning to be nearly $87 million.
The extent of intentional versus unintentional overdosing
with acetaminophen is not clear. Ostapowicz et al. (2002)
report that 68 (57%) of the 308 APAP-associated ALF
cases in their study were deemed unintentional (non-
suicidal) overdoses. Other analyses have estimated that
between 8%-26% of APAP-related overdoses are uninten-
tional (Nourjah et al. 2006), and between 6% and 30% of
unintentional overdoses are due to therapeutic misuse
(Nourjah et al. 2006; Gyamlani and Parikh 2002; Schiodt
et al. 1997). Hepatoxicity can occur even within the
maximum daily recommended dose of 4 g (Eriksson et al.
1992; Moling et al. 2006; Bolesta and Haber 2002;
Kurtovic and Riordan 2003), and is especially likely to
occur when therapeutic doses are taken under certain
conditions, such as ingesting alcohol or fasting1 (Larson
2007; Ostapowicz et al. 2002), though it may occur within
the therapeutic dose even in the absence of malnutrition or
alcohol use or abuse (Bonkovsky et al. 1994).
The US Food and Drug Administration and acetaminophen
In September 2002, the US Food and Drug Administration
(FDA) convened a Nonprescription Drug Advisory Com-
mittee (NDAC) meeting to consider safety issues
concerning OTC analgesics, including the potential for
hepatoxicity associated with acetaminophen. The NDAC
heard from William Lee, M.D., University of Texas
Southwestern Medical Center, Dallas, that there are an
estimated 1,000 to 2,000 acute liver failure cases in the US
each year, nearly a third of which are fatal.
Hepatoxicity reports received through FDA’s adverse
event reporting system (AERS) between January 1998 and
July 2001 showed that acetaminophen overdoses were
associated with large numbers of emergency department
1 FDA guidelines published in 2004 note that the risk of liver damage
increases with consumption of three or more alcoholic drinks a day
(http://www.fda.gov/cder/drug/analgesics/default.htm, accessed 5/18/
2008). Dart (2001) estimates that, since 22% of US adults use
acetaminophen each week and 5% to 10% of the population abuses
alcohol, the health-care implications of serious adverse interactions are
considerable.
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and hospital admissions and were related to an estimated
100 deaths each year (Federal Register 2006). Moore et
al.’s (2007) analysis of AERS data from 1998 to 2005
concluded that acetaminophen ranked fifth as the most
frequent suspect drug for cases involving death or serious
nonfatal outcomes.
The FDA has concluded that the following factors lead
to OTC-drug induced hepatoxicity: (1) adults taking more
than the recommended dose of acetaminophen, and in some
cases using multiple products containing acetaminophen;
(2) risk factors such as alcohol use or pre-existing liver
disease; (3) errors related to confusion over different
product formulations, dosing strengths and the use of
inappropriate dosing devices in pediatric cases (Federal
Register 2006).
International problems with acetaminophen
Acetaminophen misuse and abuse also appear to be serious
problems in the United Kingdom (UK) and Canada.
Hawkins et al. (2007) note that paracetamol (the UK name
for acetaminophen) is the most common drug taken in
overdose in the UK, accounting for 48% of poisoning
admissions to hospital, and is involved in an estimated 100-
200 deaths per year. Turvill et al. (2000) report that
paracetamol is the most common cause of intentional self-
harm in the UK, with an estimated 70,000 cases per year,
and represents a heavy burden to emergency, medical, and
psychiatric services. Myers et al. (2007) examined acet-
aminophen overdose rates in Canada between 1997 and
2002 and found an adjusted incidence of 35.1 per 100,000
population in 2002, with 69% of cases being intentional,
and 25% being unintentional.
Misuse and abuse of ibuprofen and other NSAIDs
The use of non-steroidal anti-inflammatory drugs (NSAIDs)
is also widespread, and overdosing is common. Amar and
Schiff (2007) report that NSAIDs are estimated to result in
over 100,000 hospitalizations per year, at a cost of more
than $2 billion, and are responsible for 16,500 deaths
annually in the US. Ibuprofen overdosing, although often
asymptomatic or only moderately symptomatic, can result
in serious toxicity complicated by metabolic acidosis, renal
insufficiency and/or renal failure necessitating prolonged
dialysis (see Wood et al. 2006; Volans et al. 2003; Kim et
al. 1995; Zuckerman and Uy 1995; Le et al. 1994; Downie
et al. 1993; Halpern et al. 1993).
The FDA’s 2002 NDAC heard the results of a National
Kidney Foundation study (initiated in 1995) that examined
556 articles published in the medical literature about
analgesic-related nephrotoxicity and concluded that there
should be explicit label warnings about potential renal risks
of consuming OTC NSAIDs (Federal Register 2006). The
FDA analyzed AERS cases from 1984 to 1999 involving
OTC NSAIDs and found that out of 121 cases of renal
failure, 94 involved ibuprofen–56 required hospitalization,
9 needed dialysis and 9 died. Renal failure occurred within
less than 7 days of exposure to the drug; 14 ibuprofen cases
were within the pediatric age group (Federal Register
2006).
Public knowledge about OTC analgesics
Although in the UK the incidence of paracetamol poisoning
seems to be related to its availability rather than ignorance
of its complications (Hawton et al. 1995), in the US there
appears to be little understanding and/or acceptance among
the general public that analgesic misuse or abuse can cause
real and lasting damage. Two large US national surveys
totaling 9,062 respondents–a survey conducted in September-
October 1997 by Roper Starch Worldwide for the American
Gastroenterological Association (AGA),2 and a survey
conducted in December 2002 by Harris Interactive® for
the National Consumers League (NCL)–have revealed
some disturbing consumer behaviors and opinions associ-
ated with OTC analgesics (American Gastroenterological
Association 1998; National Consumers League 2003).
In the Roper survey, 60% of the exclusive OTC-NSAID
users said they were not aware they were at risk of side
effects from NSAIDs; 29% said they did not believe they
were at risk of side effects from NSAIDs; 46% thought
OTC-NSAIDs were safer than prescription NSAIDs; 26%
said they used more than the recommended dose on the
product label; 22% said they thought warning symptoms
would precede any NSAID-induced complications.
In the Harris survey (projected to represent 175 million
US adults), 84% reported using an OTC pain reliever in the
last year and 15% reported daily use. Alarmingly, 44% said
they consumed more than the recommended dose on the
product label; 50% said they were not concerned about
potential side effects; 45% said it is important to control
pain regardless of risk; 45% said it is safe to take an OTC
pain reliever while also taking another OTC cold or flu
medication; 34% said it is safe to take an OTC pain reliever
while taking a prescription medication; almost 20% said it
is safe to take an OTC pain reliever while drinking alcohol;
30% believed there was less risk with the use of OTC
analgesics than with prescription analgesics; only 16%
reported reading the entire product label.
The responses of arthritis sufferers and heavy drinkers–
those with increased risk for side effects due to prolonged
2 The summary reported here is extracted from an article by Wilcox et
al. (2005).
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use or overuse–were particularly worrying: nearly 60% of
heavy drinkers (defined as those who consume three or
more drinks a day, five or more times a month) said they
were not concerned about side effects, and 65% reported
consuming alcohol the same day they took OTC pain
medication.
Problems associated with OTC analgesic misuse and
abuse are compounded by the fact that few consumers
accurately recall correct dosing instructions. Stumpf et al.
(2007) found that, while nearly 80% of their 104 subjects
reported using a drug product containing acetaminophen
during the past 6 months, and while 18.3% were taking an
acetaminophen-containing medicine at least once a day,
nearly 70% of the patients underestimated the maximum
recommended daily dose of regular-strength acetamino-
phen. Only 2 patients (2%) knew the correct dose of
regular-strength acetaminophen, only 3 knew the correct
dose of extra-strength acetaminophen, and 28 patients were
not sure of the maximum dose of either formulation of
acetaminophen.
Risks to the elderly are especially high
Elderly consumers are especially at risk for health problems
associated with large single doses or prolonged smaller
doses of analgesics (Francis et al. 2005), because they are
the largest consumers of prescription and OTC medicines in
general, and they take more medicines for chronic pain than
do other age groups. Furthermore, the knowledge gap is
highest among the elderly vis-à-vis the types of multiple
pain medications they may be taking and the dosing
instructions for those drugs; they are more vulnerable to
adverse drug effects in general and are more prone to
developing digestive tract complications, and they are twice
as likely to underestimate the risks associated with
prolonged analgesic misuse (American Gastroenterological
Association 1998).
Teenagers and young adults
Equally worrying are the knowledge and beliefs of teen-
agers in relation to OTC analgesics, especially since
acetaminophen is often taken in overdose by adolescents
during suicidal gestures. Myers et al. (1992) surveyed 169
high school students and found that 22% of the sample
underestimated the dose of acetaminophen necessary to
cause harm, 40.5% underestimated the potential lethality of
acetaminophen, and 17% did not believe one could ingest
enough to cause death. Huott and Storrow (1997) surveyed
adolescents aged 13-18 about OTC medicines that are
regularly found at home and revealed limited understanding
of which ones can be lethal when taken in overdose (aspirin
63%, APAP 57%, antihistamines 46%, iron 24%, camphor
22%, methyl salicylate 21%, and bismuth subsalicylate
19%).
Surprisingly, however, while adolescents may have
limited general knowledge about the toxicity and lethality
of OTC drugs, one study found that 75% of a sample of
876 teens and young adults (aged 14-27) reported that they
do read OTC drug labels and package inserts–especially
when purchasing medicines to treat symptoms requiring
immediate attention (such as stomach pain, colds/flu or
joint pain)–in order to learn about dosing instructions, side
effects, symptoms treated by the medicine and ingredients
(Nabors et al. 2004). It is therefore crucial for OTC drug
labeling to be written and presented in ways that are
cognitively accessible to adolescents and young adults, and
for warnings to be conspicuous and memorable, not least
because this age group accounts for the majority of
intentional OTC acetaminophen overdoses.
NDAC recommendations and the FDA’s 2006 proposed
rule for OTC analgesics
OTC labeling The FDA’s 2002 NDAC concluded that
labeling is a major factor in promoting the safe and
effective use of OTC analgesics. The committee was
concerned that consumers do not read labels adequately
and are often unaware of the active ingredients in medicines
they are taking. Doubts were expressed about the ability to
communicate meaningful information in the confines of a
small package label, especially to the elderly (Federal
Register 2006).
Package size and configuration limitations The FDA
announced in its 2006 Proposed Rule for OTC analgesics
that it is seeking comments on package size and package
configuration limitations as a mechanism to increase safe
use of OTC analgesics by reducing unintentional and
intentional overdose (Federal Register 2006).
Package size and configuration are particularly
important for OTC analgesic products
To decrease intentional overdosing it may be helpful to
impede impulsive behavior, such as swallowing a handful
of pills, by: (1) selling blister packs rather than bottles of
pills, (2) limiting the maximum number of tablets in each
blister pack and (3) limiting the number of pills that can be
purchased at one time. Hawton et al. (1996) found that 33
out of 80 patients (41%) had seriously contemplated taking
an overdose for less than 1 h, and patients who took more
than 25 tablets were more likely to have taken loose pills
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than pills from blister packs. Turvill et al. (2000) suggest
that blister packs sold in limited quantities offer hurdles to
impulsive suicidal actions by reducing availability and
adding time needed to ingest a toxic quantity of pills, which
might allow for reflection and a change of mind. Chan
(2000) reports that blister packs have been associated with
fewer tablets being ingested in paracetamol self-poisonings
in Hong Kong. To help prevent unintentional overdosing,
the pills can be organized in a per-dose, per-day, XX-day
system (matching instructions in the “Drug Facts” label) to
help consumers keep track of the number of doses
consumed, and warnings should be made far more
conspicuous and explicit.
Package size and configuration restrictions: The UK
experience
In September 1998, the UK introduced legislation limiting
the maximum pack size of non-effervescent tablets and
capsules containing aspirin (acetylsalicylic acid) or para-
cetamol (acetaminophen) that can be sold or supplied from
outlets other than registered pharmacies to 16×500 mg
tablets or capsules, and from registered pharmacies to 32×
500 mg tablets or capsules. If a consumer can show a bona
fide need for larger quantities (e.g., an arthritis sufferer), the
pharmacist has the discretion to permit the purchase of up
to 100 tablets (which would actually be 96 tablets in three
packs of 32 tablets). Paracetamol pack-size restrictions
were introduced in Ireland in October 2001, where packs
are limited to 12 tablets, and only one pack can be sold per
transaction.
A considerable amount of research and discussion has
taken place since 1998 to assess the effects of this
legislation, with findings being mostly positive. Hawkins
et al. (2007) reviewed 17 studies and concluded that the
legislation has predominantly reduced mortality rates,
admissions to liver units/liver transplants, hospital admis-
sions and the severity of paracetamol overdoses since 1998,
although more long-term studies are needed to fully assess
the impact of the legislation.3
Before-and-after studies by Hawton et al. in 2001 and
2004, evaluating data from September 1996 to September
1999 and September 1993 to September 2002, respectively,
concluded that the pack-size restrictions have been benefi-
cial–suicidal deaths from paracetamol and salicylates were
reduced by 22% in the year after the change in legislation
(September 1998), and this reduction persisted in the next 2
years. Liver unit admissions and liver transplants for
paracetamol-induced hepatotoxicity were reduced by about
30% in the 4 years after the legislation. Numbers of
paracetamol and salicylate tablets in non-fatal overdoses
were also reduced in the 3 years after the legislation. Large
overdoses were reduced by 20% for paracetamol and by
39% for salicylates in the 2nd and 3rd years after the
legislation.
Prince et al. (2000) analyzed data from admissions to a
liver unit in a northern England urban hospital and patients
registered in the UK for liver transplantation for para-
cetamol hepatoxicity between October 1995 and December
1999. Results indicated substantial reductions (p<0.02)4 in
the frequency of paracetamol hepatoxicity locally and
nationally after legislation went into effect in September
1998, and these reductions were not explained by changes
in referral patterns or use of N-acetylcysteine.
Turvill et al. (2000) found that for the 3 years preceding
the legislation, the number of paracetamol overdoses
presenting at a large London hospital was consistent. In
the year following the compulsory introduction of blister
packs, there was a 21% reduction in all paracetamol
overdoses and a 64% reduction in severe overdoses.
Donohoe et al. (2006) examined deliberate paracetamol
overdoses reported during two 24-month periods before and
after the legislative changes in Ireland in October 2001.
They concluded that the number of tablets taken in these
overdoses fell significantly after October 2001: fewer cases
involved 12-24 tablets and fewer cases involved more than
24 tablets.
Counter-arguments from the UK
Bateman et al. (2006) analyzed routine death and hospital
discharge data for the entire Scottish population from 1995
to 2004 and concluded that the legislation has not reduced
mortality or proportional use of paracetamol in overdose
deaths, both of which appear to have increased in Scotland
since pack-size limitations were introduced. This anomaly,
however, might be explained by the following: (1) overdose
rates in Scotland have traditionally been higher than in the
rest of the UK and (2) the majority of the paracetamol-
associated deaths from 1995-2004 were due to prescription
co-proxamol rather than OTC paracetamol.
3 Although Morgan et al. (2005) reported that paracetamol-only deaths
in England and Wales decreased from about 4.5 to 2.8 per million
between 1997 and 1999, and from about 3.1 to 2.2 per million
between 2001 and 2002, they concluded that the contribution of the
1998 regulations to this decline is not clear.
4 In the 3 years prior to September 1998, the annual rate of referrals to
the Freeman was falling by an average of 4.5 patients per year. It fell
by ten patients per year after the legislation was introduced. Also,
even though the number of referrals to the UK transplantation registry
had been increasing annually in the 3 years prior to September 1998
by an average of 7.5 patients per year, the median number of monthly
referrals fell from 3.5 to 2 (p < 0.02) after the legislation was
introduced.
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Sheen et al. (2002) have reported that while the total
mass of paracetamol and aspirin sold between 1998 and
2000 fell, that of ibuprofen increased, although the
increased ibuprofen sales did not translate into higher
mortality rates.
Papadopoulos (2004) analyzed mortality statistics for
England and Wales and concluded that while suicide attempts
using paracetamol and admissions to liver units may have
decreased following the packaging legislation, deaths from
suicide overall did not decrease, suggesting that people who
are seriously suicidal simply turn to other methods of suicide
instead of pills. Similarly, Jowett (2004) warns that self-
poisoners will choose alternative drugs (predominantly anti-
depressant and anti-psychotic sedatives) and drug “cocktails,”
leaving the problem of drug-overdose suicides unresolved by
the paracetamol pack-size legislation.
Although those bent on suicide may seek alternative
methods no matter what kind of legislation is imposed, this
should not diminish or negate the positive results that have
accrued from the pack-size legislation vis-à-vis both
intentional and unintentional overdoses. Even if such
legislation cannot provide a complete answer to drug-
induced suicides, it has still shown that it can save hundreds
of lives annually that would otherwise have been lost if no
such legislation had been in place. The fact remains that
any reduction in lives lost from acetaminophen and NSAID
overdoses is a beneficial outcome. Ultimately, as Greene et
al. (2006) point out, pack-size legislation can only work if it
is enforced. Their study revealed that 46% of patients who
had ingested a potentially toxic dose of paracetamol
obtained the tablets from pharmacy and non-pharmacy
outlets in a manner contravening the legislation.
The problem to be solved by this prototype compliance
packaging
The US Food and Drug Administration requires that
important information pertaining to each OTC drug product
be printed in a specific format in what is called a “Drug
Facts” label, and this “Drug Facts” label must be printed on
the outer packaging of the drug product, so that consumers
can read important information about the medication prior
to purchasing the product. The “Drug Facts” label includes
information about the drug’s active ingredient(s), its uses,
warnings (e.g., allergy alert(s), contraindications, side
effects, when to use or not to use the drug, when and why
to ask a doctor or pharmacist about certain medical issues
related to taking the drug, what to expect when using the
product, when to stop using the product, and special
pregnancy and breast-feeding warnings), directions for
taking the drug product, information about storing the
product and a list of the drug’s inactive ingredients.
However, one of the main concerns about the packaging
of OTC drugs is the fact that important directions and
warnings for taking a medicine are often printed only on the
outer packaging, e.g., the carton in which the product is
sold, but after purchase, consumers open up the package,
remove the pills that are inside, and frequently throw the
carton away–hence the instructions and warnings are
discarded as well, and consumers no longer have the
important warnings and dosing directions in front of them
each time they use the drug product. Cheatham and
Wogalter (2002), for example, found that study participants
said they would save the OTC medication box only about
15% of the time. In addition, more subjects reported
reading information about the drug a higher percentage of
the time before (M=63.5%) rather than after (M=27.4%)
opening and using the OTC drug for the first time.
The compliance packaging described here (Figs. 1 and 2)
solves this problem by incorporating the blister pack of pills
directly into a hinged-card system that remains attached to
the blister pack of pills for the duration of their use, thus
keeping the “Drug Facts” label, which contains the dosing
directions, warnings, etc., with the pills at all times. The
hinged card opens like a book, and the blister pack of pills
is incorporated into the right-hand leaf of the card to hold it
in place. When the product is sold, the hinged card would
be folded closed and covered with a clear plastic film to
prevent tampering, but still leave all the Drug Facts labeling
visible and readable. It would be stocked on hanging pegs
in the OTC pharmacy area.
The need for more conspicuous warnings and explicit
information about risks
The hinged-card arrangement described here (1) provides
increased surface space on which to print the “Drug Facts”
label in a larger font size than would be possible on a
regular carton; (2) provides space on which to print
enhanced, more salient warnings and directions to help
emphasize and explain to consumers why it is important to
follow the dosing directions, and what can happen when
the directions are ignored; (3) keeps the enhanced consumer
information–the additional, more conspicuous warnings and
dosing instructions–attached to the pills so they will NOT
be discarded like a carton or an inserted instructions sheet
might be.
Accessible and salient Research indicates that a product
warning is far more effective when it is easily accessible
and when users must physically interact with it during
product use (Wogalter and Young 1994; Lesch in Wogalter
2006). Studies with medication and non-medication prod-
ucts show that placement of the warning on the product
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itself, rather than on the outer carton or in package inserts,
increases the likelihood of a user noticing and reading the
warning (Barlow and Wogalter 1991; Wogalter et al. 1993,
1996) and complying with it (Wogalter and Young 1994).
Larger print size Increasing the surface area on product
containers to accommodate additional or larger labeling (for
example, by using supplemental cap labels or attaching
supplemental information tabs to bottles) has been shown to
significantly facilitate the communication of instructions and
warnings, not least because it enables the use of larger print
size, which is especially important to elderly consumers and
those with visual impairments (Barlow and Wogalter 1991;
Wogalter et al. 1993; Wogalter and Dietrich 1995; Wogalter
et al. 1996, 1999).
FDA regulations stipulate a minimum font size of 6.
However, Sheedy et al. (2005) found that optimal legibility
was attained at 10-point font size; Wogalter and Vigilante
(2003) found the optimal size to be between 7-11;
Watanabe et al. (1994) concluded that in order to enhance
readability for the elderly, OTC drug labeling should use a
vertical type size of at least 20/40 RS (6.7 pt) and letter
compression of no more than 39 characters per inch.
Conspicuous and explicit Another requirement for suc-
cessfully conveying warnings and risk information is
 
The left inside panel should 
be used for conspicuous 
educational information 
and instructions about the 
medicine, including 
prominent warnings, side 
effects, and the explicit 
consequences of misusing 
the drug. This will 
hopefully encourage 
compliant product use. 
These are the two inside 
surfaces of the hinged 
card when it is opened.   
The right-hand inside panel 
contains the blister-pack of pills 
and repeats the most important 
Directions so that they are 
immediately adjacent to the pills. 
The inside surface of the blister-
pack of pills repeats the dosage of 
each pill. This helps to emphasize 
how  many milligrams of the drug 
are being taken in each pill.  
Fig. 2 The inside panels of the
prototype compliance packaging





starts on the front of
the folded card and
continues on the back.
The key Directions for 500 mg
acetaminophen will be in the
“Drug Facts” label directly
above the pills.
The package limits the total
number of pills to 32 and
arranges the tablets in rows of 4
across x 8 down, to encourage
consumers to take no more than 
1-2 tablets every 4-6 hours (no 
more than 8 x 500 mg per day) 
for no longer than 4-8 days.
Fig. 1 The outside panels of the
prototype compliance packaging
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that the message (the words themselves) be conspicuous
and explicit. Research indicates that the use of certain
signal words, color, spacing, letter size and highlighting
all play important roles in making warnings more
prominent, salient and memorable (Braun and Silver
1995; Wogalter et al. 2002). Moreover, Laughery and
Stanush (1989) have shown that people are far more likely
to heed a warning when the information is explicit and
gives examples of the consequences of ignoring the
warning (rather than just generalized “do not...” types of
warnings).
These important principles of effective risk communication
have been confirmed by numerous studies (cf. Wogalter
2006), including research directly concerning acetamino-
phen warnings. Cheatham and Wogalter (2003) compared
the effectiveness of composite existing acetaminophen
product labels with a revised label that provided more
explicit text about the dangers of concomitant alcohol and
acetaminophen use, and incorporated several proven
characteristics of warning design enhancement. Results
indicated that significantly more respondents who were
exposed to the revised label (70%) rather than the
composite existing labels (41%) were knowledgeable
about the acetaminophen/alcohol combination hazard.
Kalsher and Wogalter (2002) found that 92% of
respondents indicated they wanted to be informed about
the organ-specific risks of OTC analgesics, and 73.3%
indicated they would take a smaller dose if they were aware
of the organ-specific risks associated with OTC analgesics.
Also, 33% said they would consult a doctor before using
OTC analgesics and 30% said they might decide not to use
the products if they were provided with information about
the organ-specific risks.
Industry considerations for compliance packaging
Manufacturing and environmental costs Manufacturers
may be hesitant to adopt alternative packaging and labeling
designs because of increased costs. Although re-tooling the
production line is initially expensive, the production costs
diminish over time. As for the environment, the blister
packing might be made with bio-degradable material rather
than regular plastic, and the prototype uses only marginally
more paper for the card arrangement than would be used, in
total surface area, for a carton. Shelf space is another
consideration. The flattened design of the prototype makes
it less bulky than a bottle, or even a carton, and the
prototype can be displayed on hanging pegs (rather than a
shelf), which is also space-saving.
Regulation Another consideration for OTC drugs is that the
packaging must comply with the Poison Prevention
Packaging Act (PPPA),5 administered and enforced by the
US Consumer Product Safety Commission. This regulation
dictates the types of unit packaging that can be used for
different drug products. For example, blister packs of
acetaminophen (500 mg) must be child resistant to 3 units;
ibuprofen (200 mg) must be child resistant to 5 units.
Conclusion
Ultimately, safety benefits to consumers will hopefully
balance any additional costs. This compliance packaging
offers a relatively inexpensive, practical method to increase
the likelihood that the OTC drug warnings and dosing
directions will be noticed, read and complied with. It may
help to: (1) make it more difficult for consumers to simply
“pop” a handful of pills; (2) make it pro-forma for
consumers to see the warnings and dosing directions each
and every time they use the product; (3) make consumers
aware of the organ-specific risks and consequences of
exceeding the dosing directions; (4) make it easier for
consumers to keep track of the number of pills they
consume per dose and per day.
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compliance packaging described in this review article.
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do not represent the views of the United States government or any
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